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Previewsinhibition by increasing spiking or by
elevating other aspects of synaptic trans-
mission (although neither was seen in the
time frame of the experiments conducted
here). A compensation of this sort could
impair global brain function and modestly
elevate the proteostatic burden on neu-
rons, resulting in a slow accumulation of
cellular deficits that results in relatively
widespread LB formation only late in life.
Although the deficit predicted by Nem-
ani et al. should be widespread, it is
possible that its impact is felt more by
some neurons than others. Some of the
most vulnerable neurons in PD—dopami-
nergic neurons in the substantia nigras
pars compacta, noradrenergic neurons
in the locus ceruleus, serotonergic neu-
rons in the raphe nuclei, and cholinergic
neurons in the basal forebrain nuclei
(Jellinger, 1991)—have enormous axonal
fields with orders of magnitude more
synaptic terminals than most neurons
(e.g., Matsuda et al., 2009). Moreover, all
of these neurons are spontaneously
active in vivo, continually releasing trans-
mitter in target structures like the striatum,
cerebral cortex, and hippocampus (Bara-
ban and Aghajanian, 1980; Chan et al.,
2007; Vinogradova et al., 1980; Williams4 Neuron 65, January 14, 2010 ª2010 Elsevieet al., 1984). This sustained transmitter
release is important to their targets, and
all of these neurons have feedback sys-
tems at their terminals (e.g., autorecep-
tors that regulate the entry of calcium trig-
gering exocytosis) to make sure that they
are doing their job. It is not difficult to
imagine that compromising the ability of
these neurons to release transmitter
might force them to work even harder
than demanded by their normal role in
brain, and that, after fifty or sixty years,
they are left with axonal pathology (Galvin
et al., 1999) and LBs.REFERENCES
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The mechanisms underlying the brain response to systemic inflammation remain unclear. In this issue of
Neuron, Serrats and colleagues demonstrate that two cell types that produce prostaglandins that act on
the brain, perivascular and endothelial cells, have an unexpectedly complex interaction in regulating the
timing and types of brain responses that occur.During systemic inflammation, there is
a stereotyped set of responses that are
mediated by the brain. These includeelevation of body temperature (fever),
anorexia, reduction of pain thresholds,
disruption of sleep cycles, and elevationof corticosteroids (Elmquist et al., 1997b).
The very fact that these responses are
so stereotyped across many types of
Neuron
Previewsinfection and that they are observed
across the mammalian line indicates their
adaptive value in fighting off infections. It
has been known since the 1940s that
inflammatory cells in the body elaborate
hormones, originally called the ‘‘endoge-
nous pyrogen,’’ that mediate these
responses, andsince the1970s that proin-
flammatory cytokines such as interleukin-
1 (IL-1), interleukin-6, and tumor necrosis
factor a are responsible for this signaling.
However, a key problem in understanding
this cascade has remained: how does the
brain receive the cytokine signals?
The blood-brain barrier (BBB) prevents
most molecules in the bloodstream from
having direct access to the brain. This is
necessary, as the brain uses for internal
signaling many of the same molecules
that are used for intercellular communica-
tion in the bloodstream. Mixing the two
signals would hopelessly muddle the
signaling capabilities of the brain. But the
BBB produces a problem: the brain must
respond to many blood-borne signals,
but has no direct access to them. This
problem is solved in several ways.
Many hormones interact with the brain
at circumventricular organs (Saper and
Breder, 1994). These are small bits of
brain tissue such as the area postrema
and organum vasculosum of the lamina
terminalis, along the edges of the cerebral
ventricles, that lack a BBB. Neurons in
these regions can respond directly to
blood-borne signals and then send their
axons through a glial barrier into the
remainder of the brain to relay the signals
(sometimes using the same molecule as
a neurotransmitter that they are moni-
toring in the blood).
Although early theories suggested this
mechanism for immune signaling to the
brain (Saper and Breder, 1994), subse-
quent evidence has not supported this
hypothesis. One of the most persuasive
linesofevidence that thecytokinesengage
a different mechanism for signaling across
the BBB has been that many of the brain
effects of immune stimulation, including
elevation of body temperature and cor-
ticosteroid responses (Elander et al.,
2009; Zhang et al., 2003), depend upon
the generation of prostaglandins, particu-
larly prostaglandin E2 (PGE2). Prostaglan-
dins are lipids, which are capable of
crossing the BBB and diffusing for short
distances in the brain. Of course, humanshave been using inhibitors of cycolo-
oxygenase (COX), the prostaglandin
synthetic enzyme, topreventCNS immune
responses (fever, hyperalgesia, etc.), for
over 100 years, in the form of aspirin and
the many other nonsteroidal anti-inflam-
matory drugs. But the circumventricular
organs lack PGE2 receptors, which are
deep within the brain (Oka et al., 2000).
Hence, the effects of immune signals on
the brain must depend upon the produc-
tion of prostaglandins, and the origin of
thoseprostaglandinshasbecomeacentral
problem in neural-immune interactions.
In the late 1990s, two theories emerged
for the origin of prostaglandins that
affect the brain. One suggested that the
endothelial cells of the blood vessels at
the blood-brain interface, mainly small
venules around the periphery of the brain,
produced cyclo-oxygenase and prosta-
glandin E2 synthase, the enzyme cas-
cade that generates PGE2, in response
to immune stimulation with either lipo-
polysaccharide (LPS) or IL-1 (Laflamme
et al., 1999; Matsumura et al., 1998). The
other theory suggested that perivascular
cells (PVCs), which line the small venules,
responded to low doses of the same
immune stimulators (Elmquist et al.,
1997a; Schiltz and Sawchenko, 2002).
PVCs are resident macrophages (Elm-
quist et al., 1997a) whose normal role is
to endocytose and destroy invading
organisms. Careful studies by Schiltz
and Sawchenko showed that low doses
of IL-1 and LPS cause expression of
COX2 in the PVCs first, and then higher
doses activate expression in the endothe-
lial cells (Schiltz and Sawchenko, 2002).
However, Yamagata and colleagues
found that PGE2 synthase was only found
in the endothelial cells (Yamagata et al.,
2001), which indicated that the two cell
types were probably engaged in a dialog
in producing PGE2 and activating brain
responses.
The new paper by Serrats and col-
leagues from the Sawchenko laboratory
(Serrats et al., 2010) takes this story
a step further, by demonstrating that this
interaction actually is more complex than
had previously been recognized, forming
something like a dance that varies across
both time and space and according to the
stimulus that incites it. To dissect the roles
of the PVCs and endothelial cells, they in-
jected liposomes containing clodronate,Neurona toxin that causes cell death, into the
lateral cerebral ventricle. The liposomes
were endocytosed by PVCs, which were
then selectively depleted.
This is where things got interesting. The
intravenous administration of a low dose
of IL-1 in PVC-depleted animals failed to
elicit COX2 expression in endothelial
cells. However a low dose of LPS caused
an intensified activation of COX2 tran-
scription in the endothelial cells. In other
words, the PVCs were necessary for
responses to low doses of IL-1, but for
low doses of LPS the PVCs appeared to
have an inhibitory effect on endothelial
expression of COX2. Prostaglandin E2
synthase expression was elevated by
both LPS and interleukin-1 in both endo-
thelial cells and perivascular cells, in
both groups of animals. Thus, because
COX2 is the rate-limiting enzyme for pros-
taglandin synthesis in the small pene-
trating blood vessels of the brain, the
increased expression of COX2 is likely to
reflect an increased capacity by the
tissue to produce PGE2 as a response
to immune stimulation. As expected,
PGE2 immunoreactivity was increased in
PVCs, but not endothelial cells, with low-
dose IL-1 challenge (and abrogated in
the animals that were depleted of PVCs).
However this same treatment enhanced
endothelial-derived PGE2 immunoreac-
tivity after low-dose LPS.
The Sawchenko group had previously
shown that PGE2 synthesis in the ventro-
lateral medulla was necessary to activate
A1 (noradrenergic) and C1 (adrenergic)
neurons, whose projections to the para-
ventricular nucleus were required for
elevation of expression of corticotrophin
releasing hormone (CRH) and c-Fos after
immune stimulation (Ericsson et al.,
1997). As expected, the activation of this
pathway by low-dose IL-1 was blocked
by depletion of PVCs, but the response
to low-dose LPS was enhanced. The
changes in expression of CRH and
c-Fos (an immediate-early gene that
signifies neuronal activation) in the para-
ventricular nucleus were mirrored by
proportional changes in circulating adre-
nocorticotrophic hormone (ACTH) and
corticosterone.
When they looked at fever responses in
the same animals, the dance became an
arabesque. Interleukin-1 produced a
biphasic response in intact animals, with65, January 14, 2010 ª2010 Elsevier Inc. 5
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Previewsan initial hypothermia followed by a hyper-
thermic period. In animals that lacked
PVCs, only the initial hypothermic
response was lost, and as might be
expected treatment with LPS yielded
a vigorous fever response that was
somewhat higher in the PVC-depleted
group. Because the temperature eleva-
tion depends upon median preoptic
neurons that respond to PGE2 via the
EP3 receptor (Lazarus et al., 2007), these
results suggest that by 2 hr after injection
there must be sufficient elevation of PGE2
in the IL-1-treated animals to cause the
fever. On the other hand, loss of the early
temperature depression, which also
depends upon PGE2 (but for which the
site of action and receptor subtype are
not yet known), may indicate that the
expression of PGE2 in the preoptic
region is delayed in the animals lacking
PVCs. This interpretation would be con-
sistent with the effects of immune stimuli
varying not just in the cell types that they
activate, but also in the timing of that
activation.
The elegant and nuanced pas de deux
between the brain and the immune system
has, of course, evolved to fight invasion by
different microbial organisms. LPS is
acomponentof thecellwall ofGram-nega-
tive organisms (such as E. coli and Salmo-
nella typhimurium), and it is sensed by
CD14 receptors that serve as an early
warning component of the innate immune6 Neuron 65, January 14, 2010 ª2010 Elsevieresponse. IL-1, by contrast, is a cytokine
that is expressed by immune cells,
including tissue macrophages (like PVCs),
soon after an immune response is trig-
gered, but would be expected to be elabo-
rated during the first hour after the invasion
of virtually any microbe. In life, LPS in the
bloodstream during sepsis would there-
fore be detected by endothelial cells that
express the CD14 receptor, which would
activate perivascular microglia. These
would in turn secrete IL-1, which would
predominantly activate additional nearby
perivascular cells and amplify their
response, while simultaneously quieting
the response of the endothelial cells.
Of course, all of this workwas donewith
low doses of the stimuli, and the relation-
ships could change as the dose of the
stimulus increased. Also, as Serrats and
colleagues point out, the nature of the
signals interchanged by these two cell
types and their intracellular signaling cas-
cades remain a major frontier. However,
as we unravel this story, it is clear that
the nature of the brain response to
immune stimuli depends upon the stimuli
that are applied, their dosage, and on
the types of responses that aremeasured,
and in real-life infections, both stimuli and
responses differ dynamically over time.
The challenge for the future is to under-
stand how this elaborate dance adapts
mammals to ward off the challenges of
microbial invasion.r Inc.REFERENCES
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